Free Trial

ADMA Biologics (ADMA) Stock Price, News & Analysis

ADMA Biologics logo
$16.75 -1.79 (-9.65%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$16.96 +0.21 (+1.25%)
As of 08/7/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ADMA Biologics Stock (NASDAQ:ADMA)

Key Stats

Today's Range
$14.62
$17.52
50-Day Range
$16.73
$21.87
52-Week Range
$11.55
$25.67
Volume
11.89 million shs
Average Volume
2.65 million shs
Market Capitalization
$4.00 billion
P/E Ratio
19.48
Dividend Yield
N/A
Price Target
$27.67
Consensus Rating
Buy

Company Overview

ADMA Biologics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

ADMA MarketRank™: 

ADMA Biologics scored higher than 86% of companies evaluated by MarketBeat, and ranked 132nd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ADMA Biologics has received no research coverage in the past 90 days.

  • Read more about ADMA Biologics' stock forecast and price target.
  • Earnings Growth

    Earnings for ADMA Biologics are expected to grow by 35.29% in the coming year, from $0.51 to $0.69 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ADMA Biologics is 19.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.80.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ADMA Biologics is 19.48, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.88.

  • Price to Book Value per Share Ratio

    ADMA Biologics has a P/B Ratio of 11.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.06% of the outstanding shares of ADMA Biologics have been sold short.
  • Short Interest Ratio / Days to Cover

    ADMA Biologics has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in ADMA Biologics has recently decreased by 10.90%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    ADMA Biologics does not currently pay a dividend.

  • Dividend Growth

    ADMA Biologics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.06% of the outstanding shares of ADMA Biologics have been sold short.
  • Short Interest Ratio / Days to Cover

    ADMA Biologics has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in ADMA Biologics has recently decreased by 10.90%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    ADMA Biologics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for ADMA Biologics this week, compared to 9 articles on an average week.
  • Search Interest

    27 people have searched for ADMA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    18 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,644,269.00 in company stock.

  • Percentage Held by Insiders

    Only 3.50% of the stock of ADMA Biologics is held by insiders.

  • Percentage Held by Institutions

    75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ADMA Biologics' insider trading history.
Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

ADMA Stock News Headlines

Critical AI announcement set to ignite AI 2.0
Markets are jittery. Rallies fade. Sectors rotate overnight. And the true impact of new tariffs and policy shifts hasn’t even hit the data yet. That’s why smart traders are turning to a strategy built for exactly this kind of market—fast, simple, and designed to react to real price action, not predictions.
Adma Biologics (ADMA) Q2 Revenue Up 14%
ADMA Biologics, Inc. (ADMA) Q2 2025 Earnings Call Transcript
ADMA Biologics Q2 2025 Earnings: EPS of $0. ...
See More Headlines

ADMA Stock Analysis - Frequently Asked Questions

ADMA Biologics' stock was trading at $17.15 at the start of the year. Since then, ADMA shares have decreased by 2.3% and is now trading at $16.75.

ADMA Biologics Inc (NASDAQ:ADMA) posted its earnings results on Wednesday, May, 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by $0.02. The firm's quarterly revenue was up 40.2% compared to the same quarter last year.
Read the conference call transcript
.

ADMA Biologics' top institutional investors include Allspring Global Investments Holdings LLC (1.39%), Perpetual Ltd (1.21%), Vaughan Nelson Investment Management L.P. (0.75%) and Bank of New York Mellon Corp (0.63%). Insiders that own company stock include Adam S Grossman, Brian Lenz, Jerrold B Grossman, Kaitlin M Kestenberg-Messina, Young Kwon, Brad L Tade, Lawrence P Guiheen, Steve Elms and Bryant Fong.
View institutional ownership trends
.

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
5/07/2025
Today
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ADMA
CIK
1368514
Employees
530
Year Founded
N/A

Price Target and Rating

High Price Target
$32.00
Low Price Target
$25.00
Potential Upside/Downside
+65.2%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.85
Trailing P/E Ratio
19.48
Forward P/E Ratio
32.84
P/E Growth
N/A
Net Income
$197.67 million
Net Margins
44.06%
Pretax Margin
30.64%
Return on Equity
43.60%
Return on Assets
29.93%

Debt

Debt-to-Equity Ratio
0.22
Current Ratio
6.58
Quick Ratio
3.36

Sales & Book Value

Annual Sales
$426.45 million
Price / Sales
9.38
Cash Flow
$0.49 per share
Price / Cash Flow
34.25
Book Value
$1.48 per share
Price / Book
11.32

Miscellaneous

Outstanding Shares
238,730,000
Free Float
230,378,000
Market Cap
$4.00 billion
Optionable
Optionable
Beta
0.38

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:ADMA) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners